Johnson & Johnson
Researches, manufactures, and sells prescription medicines for oncology, immunology, and other conditions, plus surgical equipment, orthopaedic devices, and contact lenses globally.
As of Sep 2, 2026
Summary
Johnson & Johnson is a diversified healthcare company operating across pharmaceuticals, medical devices, and consumer health. The stock is trading with a neutral technical bias at $271.19, having gained 7.1% over the past month and 56.5% over the past year, with a market capitalisation of $654 billion.
Price history
As of Sep 1, 2026
Performance
+1.48%
-0.71%
+7.12%
+22.27%
+33.16%
+56.53%
As of Sep 1, 2026
Technical indicators
- 60.8
- -0.21Bearish
- 50: 258.53 · 200: 232.22Bullish
- $263.83 / $273.55
Technical Bias
Johnson & Johnson's technical setup is mixed. The moving averages are tracking bullish with the 50-day above the 200-day, but MACD momentum has turned slightly negative, while RSI sits neutrally at 60.8. This derived technical read suggests no clear directional conviction at present, with the stock trading near resistance at $273.55 and support anchored at $263.83.
A transparent read of the indicators below — not a prediction or recommendation.
As of Sep 1, 2026
Fundamentals
- $654B
- 30.85
- $8.79
- 21.48%
- +6.6%
- $19.7B
- 0.23
- $169.49 – $275.11
- 2.02%
- Aug 25, 2026
- Oct 13, 2026 (40 days)
As of Sep 2, 2026
Upcoming catalysts
- Earnings report
As of Sep 2, 2026
Latest news
As of Sep 2, 2026
MonkeyTrade's Take on Johnson & Johnson
Short-term outlook
The short-term setup leans mildly bullish but not decisively: J&J sits well above both its 50-day ($258.53) and 200-day ($232.22) averages after a strong +7.1% month, though the MACD's bearish cross hints at fading momentum near the top of its range. A push through $273.55 resistance would confirm the uptrend is still intact, while a slip below $263.83 support would signal the pullback is deepening. No earnings catalyst is imminent, with the next report not due until October 2026.
Medium-term outlook
Johnson & Johnson pairs healthy 6.6% revenue growth and a solid 21.5% profit margin with a 2.0% dividend, but a 30.85 P/E prices in a fair amount of optimism already, and the neutral technical lean suggests the market isn't yet rewarding that growth with fresh momentum. Over the next few quarters this looks like a steady, income-supported hold-the-line story rather than a breakout. A clear pickup in the technical trend would be the signal that sentiment is starting to catch up with the fundamentals.
Key risks
- Ongoing talc-related litigation remains a headline risk, with recent verdict news pointing to continued legal exposure for the company.
- The stock is trading near the top of its 52-week range at $271.19 against a high of $275.11, which can leave less room for error if sentiment shifts.
- A price-to-earnings ratio of 30.85 sits well above the company's low beta of 0.23, meaning the shares are priced richly relative to how defensively they tend to trade.
- Comparisons in recent coverage to peers like Procter & Gamble on dividend growth suggest JNJ's income story may be seen as less compelling by some investors, which could weigh on relative demand for the stock.
About Johnson & Johnson
Johnson & Johnson is a US healthcare company listed on the NYSE under the ticker JNJ. Operating in the drug manufacturing space, it ranks among the largest names in the healthcare sector, with a market capitalisation of $654B underlining its scale and standing within the industry.
Looking at the key figures, JNJ trades on a price-to-earnings ratio of 30.85, which gives a sense of how the market is valuing its earnings relative to the share price. The stock also carries a dividend yield of +2.0%, offering investors a measure of the income return generated alongside any share price movement. Together, these figures provide a snapshot of how the market currently views Johnson & Johnson's earnings and shareholder returns.
How to trade Johnson & Johnson
Shares like this are usually traded as CFDs. Compare regulated brokers that offer share CFDs — weigh spreads, fees and platforms before you open an account.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk. How we build these pages.